Healthcare Services company Vimta Labs announced consolidated Q4FY24 & FY24 results:
Q4FY24 Financial Highlights:
- Total Income for Q4FY24 was at Rs 802 million
- EBITDA for Q4FY24 was Rs 249 million; EBITDA margin was at 31.1%
- Q4FY24 PAT was at Rs 124 million
- Basic EPS in Q4FY24 was Rs 5.6
FY24 Financial Highlights:
- Total Income for FY24 was at Rs 3,223 million
- EBITDA for FY24 was Rs 908 million; EBITDA margins at 28.2%
- FY24 PAT was at Rs 410 million
- Basic EPS was Rs 18.5 in FY24
- Cash flow From Operations at Rs 609 million for FY24; FY24 Capex at Rs 763 million
- Cash and Cash equivalents at Rs 258 million as of 31st March 2024
- Debt to Equity ratio 0.06x
Commenting on results, Harita Vasireddi, Managing Director, Vimta Labs Limited, said: “Q4 maintained good recovery after H1 being harsh on us. Having a strong and resilient business model has helped us strive through some headwinds and get back to the historical figures.
Our services to the Pharmaceutical industry have seen a promising uptick, demonstrating growth in both pre-clinical and analytical services. We have recently expanded our offerings to include clinical trials, which we anticipate will be a major driver of future growth.
The Food segment experienced initial setbacks due to supply chain disruptions caused by various external factors. However, this segment has begun to recover and shows promise for continued improvement. Our new Electronics and Electrical testing division delivered strong results, while our other segments have gone through some corrections in services and their scale.
Looking forward, we are confident in our ability to achieve significant growth. While FY24 presented unforeseen challenges, we are optimistic that FY25 will be a year of robust expansion for the company.”